Finding Better Treatments for Bladder Cancer
We are pleased to report that the FDA has accepted for review our BLA for N-803 + BCG for BCG-Unresponsive NMIBC CIS. If approved, N-803 plus BCG would be the first immunotherapy combination for this indication in 23 years that can be delivered directly to the bladder to induce natural killer cells and T cells.
ImmunityBio is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells.
Our COVID-19 Research
Our researchers are developing COVID-19 vaccines that are designed to be more practical to make, store, and distribute than existing vaccines, with the potential to protect people from current and future SARS-CoV-2 variants and also be a boost to current COVID-19 vaccines.
Solutions for PatientsMany therapies for treating cancer and infectious disease severely weaken the immune system—the human body’s most important natural disease-fighting weapon. But ImmunityBio creates targeted, personalized immunotherapies that are designed to strengthen the immune system and enable it to outsmart your disease.
Opportunities for Trial InvestigatorsImmunotherapies and cell therapies are key to future cancer treatments. Our investigational IL-15 superagonist, N-803, and NK-92®-engineered cells have demonstrated wide therapeutic potential across multiple tumor types, and, in clinical studies, have proven to be well-tolerated, making them ideal for clinical trial investigations.
Solutions for Research ScientistsOur NK-92® cell line provides a versatile bioanalytical testing solution that helps researchers develop functional killing assays that are more consistent and reliable than donor blood and reporter gene assays.
At ImmunityBio, we envision a day when we no longer fear cancer, but are able to conquer it, thanks to the biological wonder that is the human immune system. Our scientists are working to develop remarkable new therapies that harness that inherent power by amplifying both branches of the immune system, attacking cancerous or infected cells today while building immunological memory for tomorrow. The goal: to reprogram the patient’s immune system and treat the host rather than just the disease.
ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it.
A Robust Clinical Pipeline
ImmunityBio's investigational immunotherapies are currently being studied for cancer and infectious disease in a range of clinical trials at various stages.
Latest News & Events
ImmunityBio Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma In Situ
This acceptance represents the first regulatory filing for N-803, an IL-15 superagonist, which was granted...
ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
Data from trials underscore ImmunityBio’s vision of activating NK cells and T cells to advance care in...
Jefferies Healthcare ConferenceDate: Friday, June 10Time: 8:30 am ESTLocation: New York, NY To download the...